ASCO Endorses CAP’s Guidelines for HPV Testing in Head and Neck Carcinomas The American Society of Clinical Oncology has endorsed the clinical guidelines developed by the College of American Pathologists for human papillomavirus (HPV) testing with head and neck cancers. HPV tumor status should be determined for newly diagnosed oropharyngeal squamous cell carcinomas, with testing performed by surrogate marker p16 immunohistochemistry either on the primary tumor or from cervical nodal metastases if an oropharyngeal primary tumor is present. Results are positive with at least 70 percent nuclear and cytoplasmic expression at least moderate to strong intensity. Confirmatory testing should be at the discretion of the pathologist and/or treating clinician. HPV tumor status is not necessary in nonsquamous carcinomas of the oropharynx or non–oropharyngeal squamous cell carcinomas of the head and neck. If there is uncertainty of histologic type or a poorly differentiated oropharyngeal tumor is nonsquamous, HPV tumor status testing should be at the discretion of the pathologist and/or treating clinician. USPSTF Reaffirms Syphilis Screening in All Pregnant Women The U.S. Preventive Service Task Force reaffirms its 2009 recommendation for syphilis screening early in pregnancy, concluding that there is convincing evidence that screening for syphilis infection in pregnant women provides […]